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Abstract: According to the World Health Organization (WHO), the global nutrition report shows
that whilst part of the world’s population starves, the other part suffers from obesity and
associated complications. A balanced diet counterparts these extreme conditions with the proper
proportion, composition, quantity, and presence of macronutrients, micronutrients, and bioactive
compounds. However, little is known on the way these components exert any influence on our
health. These nutrients aiming to feed our bodies, our tissues, and our cells, first need to reach
mitochondria, where they are decomposed into CO2 and H2O to obtain energy. Mitochondria are
the powerhouse of the cell and mainly responsible for nutrients metabolism, but they are also the
main source of oxidative stress and cell death by apoptosis. Unappropriated nutrients may support
mitochondrial to become the Trojan horse in the cell. This review aims to provide an approach to
the role that some nutrients exert on mitochondria as a major contributor to high prevalent Western
conditions including metabolic syndrome (MetS), a constellation of pathologic conditions which
promotes type II diabetes and cardiovascular risk. Clinical and experimental data extracted from
in vitro animal and cell models further demonstrated in patients, support the idea that a balanced diet,
in a healthy lifestyle context, promotes proper bioenergetic and mitochondrial function, becoming
the best medicine to prevent the onset and progression of MetS. Any advance in the prevention and
management of these prevalent complications help to face these challenging global health problems,
by ameliorating the quality of life of patients and reducing the associated sociosanitary burden.
Keywords: mitochondria; metabolic syndrome; mitochondrial dysfunction; balanced diet; nutrients;
lifestyle
1. Introduction
In the last decades, global dietary patterns have experienced a transition towards increasingly
Westernized and less healthier diets. This trend is linked to the substantial increase in the prevalence of
non-communicable diseases (NCDs) such as type II diabetes (T2D) or cardiovascular disease (CVD) [1].
During the last 40 years, the global prevalence of T2D has almost doubled, from 4.7% in 1980 to 8.5%
in 2014. Likewise, the number of deaths attributed to CVD (mainly coronary heart disease, stroke,
and rheumatic heart disease) has increased from 14.4 million in 1990 to 17.5 million, being the number
1 cause of death globally [2].
The metabolic syndrome (MetS), a cluster of pathologic conditions that raise the risk of CVD
and T2D [3], has been emerged as a health problem in modern society, associated with enormous
social, personal and economic burden in both the developing and developed world [4]. Currently,
MetS is calculated to affect 25% of the global population [5] and all the epidemiological studies have
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demonstrated its prevalence increases with age [6]. Additionally, the growing age of the population in
first world societies will increase such trends in coming years.
International food organizations have traditionally focused on food security and micronutrient
deficiency. However, diet-related health burdens contributing to the above-mentioned diseases are now
surpassing those due to undernutrition in nearly every region of the world. Therefore, the establishment
of healthy dietary patterns is a global priority to reduce the onset of these diseases [7].
There are plenty of studies establishing healthy dietary patterns [1]. However, scarce knowledge
is available on the way these nutrients underscore or promote our health. First, because there is a
wide panoply of nutrients and, second, because each one of them can trigger a multitude of effects,
organ, tissue, cell, and even molecule specific. However, a universal fact is that all of them need to be
processed into small subunits and metabolized by mitochondria to obtain energy. Thus, mitochondrial
function is key to understand dietary effects in our organism and, at the same time, understanding
how dietary patterns and nutrients influence mitochondrial function is essential to establish causal
relationships between food and health.
The diet’s impact on mitochondrial function has been widely studied due to its role as a powerhouse
of the cell and its involvement in nutrients’ metabolism. In fact, mitochondria are critical in the
maintenance of metabolic flexibility, efficient switches in metabolism depending on the environmental
demand (feeding/fasting cycles) [8]. Moreover, also the intake amount (p.e. high-fat and/or sugars
diet) conditionate mitochondrial function [9]. Additionally, micronutrients (the ~40 essential vitamins,
minerals, fatty acids, and amino acids) and bioactive compounds, must be considered in a balanced
diet to get an optimal cell–mitochondrial–metabolic axis function [10].
These dietary considerations are closely related to the manifestation of the most common NCDs [11],
including MetS [12], where the mitochondrial dys(function) can be considered a common hallmark.
Consequently, the aim of this work is to review the role of some nutrients, easily incorporable in a
balanced diet, over mitochondrial (dys)function and its impact on MetS. For this purpose, we herein
have reviewed data extracted from experimental and clinical studies published in PubMed and Google
Scholar database, from inception to July 2020, to document the principal examples of nutrients’ effect
on mitochondrial activity and their influence on MetS.
2. A Healthy Diet
Diet is the most significant single risk factor for disability and premature death [13]. Dietary choices
contribute to the development of pathologic conditions such as hypertension, hypercholesterolemia,
overweight/obesity, and inflammation, which in turn increase the risk for associated diseases, including
CVD or T2D. Several studies have demonstrated the causal link between the global shift towards
Westernized dietary patterns, characterized by high intakes of red and processed meat, pre-packaged
foods, sweets, and refined grains, and lacking in fruits and vegetables, whole-grains, fish, and nuts,
and the increased prevalence of these diet-related chronic diseases in the last decades [1,14].
Dietary changes recommended by the World Health Organization (WHO) include balancing
energy intake, limiting saturated and trans fats, and shifting toward unsaturated fats consumption,
increasing intake of fruits and vegetables, and limiting the consumption of sugar and salt. These dietary
patterns are naturally occurring in certain world regions, as it is the case of the Mediterranean diet
(MedDiet) and traditional Asian diets such as Korean, Chinese, and Japanese diets. Both the MedDiet
(rich in fish, monounsaturated fats from olive oil, fruits, vegetables, whole grains, and legumes/nuts)
and traditional Asian diets (composed of rice and other whole grains, fermented food, soy, fruits
and vegetables, fish and seafood) [1] have moderate to strong evidence for preventing T2D and
MetS, decreasing cancer and CVD incidence and mortality, decreasing overall mortality, and treating
obesity [15–18]. Moreover, healthy dietary patterns have also been developed based on nutrient intake
studies and their outcomes, as it is the case of DASH (Dietary Approaches to Stop Hypertension) [19]
and MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diets [20], among others.
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At the molecular level, a healthy diet is characterized by the consumption of appropriate
proportions of macronutrients (carbohydrates, proteins, and fats) to support energetic and physiologic
functions, sufficient micronutrients (vitamins and mineral) and hydration, to meet the physiologic
needs of the body [1]. Additionally, there is increasing evidence of the beneficial role of bioactive
compounds, such as polyphenols or lycopene, in a healthy diet to prevent diseases. These molecules,
generally natural and non-nutritive compounds, can be found in small quantities in plants and
lipid-rich foods, and are essential to fight age-related and chronic diseases [21].
3. Metabolic Syndrome (MetS)
The MetS is not a disease per se, but a constellation of pathologic conditions that raises the risk of
CVD by 1.5–2.5 fold [22] and T2D by 3–20 fold, depending on the numbers of pathologic factors [23].
To be diagnosed with MetS, at least three of the five deregulations shown in Table 1 must be present in
the patient [24].
Table 1. Risk factors associated with metabolic syndrome and definition of the parameters for
its diagnosis.
Risk Factor Parameters Definition (Male/Female)
Central obesity Waist circumference 1
America: ≥102 cm/≥88 cm
Asia: ≥90 cm/≥80 cm
Europe: ≥94 cm/≥80 cm
Africa: ≥94 cm/≥80 cm
Middle East: ≥94 cm/≥80 cm
Hypertriglyceridemia Triglyceride concentrations ≥150 mg/dL
Low HDL-cholesterol levels HDL-cholesterol levels ≤40 mg/dL/<50 mg/dL
Hypertension Systolic/diastolic blood pressure ≥130/85 mm Hg
Hyperglycemia Fasting plasma glucose ≥100 mg/dL
1 The definition of this measure varies among regions. HDL = High density lipoprotein.
The determining factors for the development of MetS are, in order of relevance/influence: weight,
genetics, aging, and lifestyle [25]. Based on that, risk factors associated with MetS can be reduced by
the introduction of a balanced-diet and some regular exercise [26].
4. Mitochondria in Health and Disease
Mitochondria are unique structures in the cell, originally alpha-proteobacterium phagocyted by
a eukaryotic progenitor [27]. Since then, proper mitochondrial activity is critical for the survival of
the eukaryotic cell. In fact, mitochondrial deregulation has been described as a hallmark underlying
several complex diseases, since mitochondrial dysfunction can trigger, by its own, oxidative stress,
bioenergetic failure, inflammation, protein accumulation, and cell death [28], common aspects in
metabolic disorders, such as MetS (Figure 1). That is why the nature of mitochondrial disorders
underlies the numerous roles that mitochondria play.
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Figure 1. Mitochondrial (dys)function factors. Mitochondrial dysfunction is characterized by the 
combination of some of the processes described above and plays a central role in several diseases, 
such as metabolic syndrome. All these processes are closely related, usually affecting one each other 
and rarely having isolated effects. Oxidative stress leads to the accumulation of reactive oxygen species 
(ROS). In turn, high amount of ROS might trigger DNA mutations. Mitochondrial (dys)function can 
also be associated to reduced mitochondrial biogenesis through the decreased expression of 
mitochondrial genes. Moreover, altered proteostasis (biogenesis, folding, trafficking, and degradation 
of mitochondrial proteins) is common. Another frequent consequence is an energy imbalance limiting 
the ATP supply. Furthermore, mitochondrial (dys)function may condition mitochondrial fusion-
fission processes compromising mitochondrial renewal and material exchange. Similarly, impaired 
mitophagy triggers the accumulation of non-functional mitochondria. Finally, mitochondrial altered 
Ca2+ flux and buffering, disrupt communication with other organelles such as endoplasmic reticulum 
and, in case of calcium release into the cytoplasm, the potential trigger of cell death. 
4.1. Mitochondrial (Dys)Functions 
The best-known mitochondrial function is energy production, through the generation of ATP 
molecules, via oxidative phosphorylation. The mitochondrial matrix houses the Krebs cycle (KC) 
enzymes, important producers of electron donors such as NADH and FADH2. These molecules bring 
electrons to the mitochondrial respiratory chain (MRC), formed by four complexes (I-IV), that pump 
protons from the mitochondrial matrix into the inner membrane space through sequential redox 
reactions that finally reduce O2 into H2O at complex IV and, the complex V or ATP synthase, uses the 
accumulated proto-gradient energy to phosphorylate ADP into ATP (chemiosmotic theory of 
Mitchell). 
One of the major cell producers of NADH is the oxidation of fatty acids (FA) to acyl-CoA, a 
process called β-oxidation, which takes place in the mitochondrial matrix. The acetyl-CoA resulting 
from this process can enter the KC and get oxidized, coupled to the production of reducing power 
[29]. Furthermore, alterations in these metabolic routes have also been widely described in cell and 
animal models, as well as in patients suffering the most prevalent NCDs such as heart failure, T2D 
[30], or MetS [31,32]. 
Figure 1. Mitochondrial (dys)function factors. Mitochondrial dysfunction is characterized by the
combination of some of the processes described above and plays a central role in several diseases,
such as metabolic syndrome. All these processes are closely related, usually affecting one each
other and rarely having isolated effects. Oxidative stress leads to the accumulation of reactive
oxygen species (ROS). In turn, high amount of ROS might trigger DNA mutations. Mitochondrial
(dys)function can also be associated to reduced mitochondrial biogenesis through the decreased expression
of mitochondrial genes. Moreover, altered proteostasis (biogenesis, folding, trafficking, and degradation
of mitochondrial proteins) is common. Another frequent consequence is an energy imbalance limiting
the ATP supply. Furthermore, mitochondrial (dys)function may condition mitochondrial fusion-fission
processes compromising mitochondrial renewal and material exchange. Similarly, impaired mitophagy
triggers the accumulation of non-functional mitochondria. Finally, mitochondrial altered Ca2+ flux and
buffering, disrupt communication with other organelles such as endoplasmic reticulum and, in case of
calcium release into the cytoplasm, the potential trigger of cell death.
4.1. Mitochondrial (Dys)Functions
The best-known mitochondrial function is energy production, through the generation of ATP
molecules, via oxidative phosphorylation. The mitochondrial matrix houses the Krebs cycle (KC)
enzymes, important producers of electron donors such as NADH and FADH2. These molecules bring
electrons to the mitochondrial respiratory chain (MRC), formed by four complexes (I-IV), that pump
protons from the mitochondrial matrix into the inner membrane space through sequential redox
reactions that finally reduce O2 into H2O at complex IV and, the complex V or ATP synthase, uses the
accumulated proto-gradient energy to phosphorylate ADP into ATP (chemiosmotic theory of Mitchell).
One of the major cell producers of NADH is the oxidation of fatty acids (FA) to acyl-CoA, a process
called β-oxidation, which takes place in the mitochondrial matrix. The acetyl-CoA resulting from
this process can enter the KC and get oxidized, coupled to the production of reducing power [29].
Furthermore, alterations in these metabolic routes have also been widely described in cell and animal
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models, as well as in patients suffering the most prevalent NCDs such as heart failure, T2D [30],
or MetS [31,32].
Secondarily, these redox reactions generate reactive oxygen species (ROS) (Figure 2). Low ROS
increase can trigger healthy physiological responses by activating complex transcriptional cascades of
stress resistance, cell proliferation, and differentiation pathways [33]. However, when cells overproduce
ROS, those can trigger pathologic consequences by promoting damage of cellular compounds (in sugars,
lipids, proteins, or nucleic acids) [34,35], thus impairing cell proliferation, differentiation, and apoptosis,
among others [36]. Additionally, mitochondria can trigger or amplify by their own cell death signals
triggered by an alternative source of damage. Altogether, these effects may have a deep impact in
mitochondrial deregulation and derived diseases, including MetS [37].
Nutrients 2020, 12, x FOR PEER REVIEW 5 of 39 
 
             
  tri ger healthy physiological responses by activating complex transcriptional cascades 
of stres  resistance, ce l prolifer tion, and differentiation pathways [33]. However, when cells 
overprodu e ROS, those can trigger pathologic c nsequences by promoting damage of cellular 
compounds (in sugars, lipids, proteins, or nucleic acids) [34,35], hus impairing cell prolifera ion, 
differentiation, and apopt sis, among others [36]. Additionally, mitochondr a can trigger or amplify 
by th ir own cell death s gnals t iggered by an alternative source of damage. Altogether, these effects 
ay have a deep impac  in mitochondrial d regulation a d derived diseases, including MetS [37]. 
 
Figure 2. Main sources of mitochondrial reactive oxygen species (ROS). Mitochondrial respiratory 
chain (MRC) is composed of four enzyme complexes (I–IV). Electrons donated from NADH and 
FADH2 in the Krebs cycle are transferred at complex I and II respectively, and consecutively to 
complex III and IV. This electrons transfer is coupled with protons transport across the inner 
membrane, generating a proton-gradient, allowing ADP phosphorylation through ATP synthase 
(complex V). Oxygen metabolism generates superoxide anion (.02-), which in turn is conversed into 
hydrogen peroxide (H2O2) by SOD (superoxide dismutase) and then converted into water thanks to 
the action of some of the antioxidant enzymatic defenses such as catalase (CAT) or the glutathione 
peroxidase (GPx) reductase (GPr) system. Excessive ROS production can oxidize proteins, lipids, or 
mitochondrial DNA (mtDNA), eventually leading to mitochondrial dysfunction and cell death. 
To fight oxidative stress, understood as the imbalance between ROS production and 
antioxidants in favor of ROS species, cells have several molecules involved in the antioxidant defense 
system. The enzymatic barrier includes superoxide dismutase (SOD), catalase (CAT), glutathione 
reductase (GR), and glutathione peroxidase (GPx). Whilst other barriers, non-enzymatic antioxidants 
molecules, are vitamins E and C, glutathione (GSH), and various carotenoids and flavonoids [4], 
present in foods and beverages. 
The proton leak generated in the MRC is mainly used to produce ATP but can also be used for 
thermogenesis purposes or to reduce the mitochondrial membrane potential, aiming to protect cells 
from oxidative stress [38]. The uncoupling proteins (UCPs) are a family of 5 proteins responsible for 
uncoupling and widely distributed in specific tissues. In fact, several studies in rodents and patients 
demonstrated abnormal expression or activity of UCPs related to obesity [39] and T2D [40]. 
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co lex III and IV. This electrons transfer is coupled with protons transport across the inner membrane,
generating a proton-gradient, allowing ADP phosphorylation through ATP synthase (complex V).
Oxygen metabolism generates superoxide anion (·02−), which in turn is conversed into hydrogen
peroxide (H2O2) by SOD (superoxide dismutase) and then converted into water thanks to the action of
some of the antioxidant enzymatic defenses such as catalase (CAT) or the glutathione peroxidase (GPx)
reductase (GPr) system. Excessive ROS production can oxidize proteins, lipids, or mitochondrial DNA
(mtDNA), eventually leading to mitochondrial dysfunction and cell death.
To fight oxidative stress, understood as the imbalance between ROS production and antioxidants
in favor of ROS species, cells have several molecules involved in the antioxidant defense system.
The enzymatic barrier includes superoxide dismutase (SOD), catalase (CAT), glutathione reductase
(GR), and glutathione peroxidase (GPx). Whilst other barriers, non-enzymatic antioxidants molecules,
are vitamins E and C, glutathione (GSH), and various carotenoids and flavonoids [4], present in foods
and beverages.
The proton leak generated in the MRC is mainly used to produce ATP but can also be used for
thermogenesis purposes or to reduce the mitochondrial membrane potential, aiming to protect cells
from oxidative stress [38]. The uncoupling proteins (UCPs) are a family of 5 proteins responsible for
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uncoupling and widely distributed in specific tissues. In fact, several studies in rodents and patients
demonstrated abnormal expression or activity of UCPs related to obesity [39] and T2D [40].
Interestingly, mitochondrial functions reach far beyond bioenergetics. Mitochondria are the key
organelles in iron metabolism, involved in heme and Fe-S clusters synthesis [41], essential structures in
oxygen transport, MRC, and DNA repair machinery.
Moreover, mitochondria regulate Ca2+ homeostasis, a key factor regulating aerobic metabolism
and one of the apoptosis triggering factors [42,43]. Alterations in these pathways are linked to
NCDs [44,45].
For all the above mentioned, mitochondria are key organelles for cell survival and adaptation
to changing environmental conditions. Thus, for instance, high energy requirements activate
mitochondrial biogenesis, induce the generation of new MRC units, and trigger an integrated
physiological response of metabolic and functional remodeling. Several molecules are involved in
the detection of specific signals of mitochondrial activity, such as NAD+:NADH, AMP:ATP ratios,
or acetyl-CoA levels. That is why alterations in this fragile equilibrium conduct to a dysregulated
mitochondrial activity, leading to the altered pathophysiological response observed in, among
others, MetS.
Similarly, mitochondrial activities depend on the abundance of these organelles, their morphology,
and their functional properties, regulated, among others, by mitochondrial dynamics [46–48].
Mitochondria are permanently fusing and fissioning with each other, allowing the renewal of genetic,
structural, and functional components. It is especially the mitochondrial fusion process, which has
been reported to allow the exchange of mitochondrial content, including mitochondrial DNA (mtDNA),
which may buffer partial defects and transient stresses [49,50]. The loss of fusion and fission abilities
results in altered mitochondrial populations, which leads to the most common NCDs [51].
To summarize, mitochondrial dysfunction can be due to several levels of deficiency and lead
to different pathological features. All their levels of function are closely related, affecting one each
other, rarely having isolated effects. In the case of MetS, reduced biogenesis conducing to variations in
mitochondrial number, altered membrane potential, leading to defective energy production and defects
in the activity of oxidative proteins, has been reported, all together linked with the accumulation of
ROS in cells and tissues [52].
4.2. Some Interactions with Other Cell Structures
Mitochondria are not isolated organelles inside the cell, so interactions with other structures
must be considered in health and disease. For instance, interactions with lysosomes [53] allow the
degradation and turnover of defective or unnecessary mitochondrial by mitophagy, important to
maintain mitochondrial quality control (MQC). The failure of the MQC system has been described
in NCDs patients [54–56], demonstrating the importance of mitochondrial interactions with other
eukaryotic cell structures.
Another important interaction of mitochondria to support cell functionality is with the endoplasmic
reticulum (ER) [57], also known as mitochondria-associated membranes, MAMs, which allows another
level of organelle and cell regulation. Alterations in MAMs have been demonstrated in NCDs
patients [58–60] due, in part, to increased ER stress but also to mitochondrial dysfunction.
4.3. Some Mitoregulators
4.3.1. Epigenetics and Sirtuins
Epigenetic modifications in DNA, which include acetylation, methylation, and ubiquitination,
among others [61], determine the transcriptional machinery accessibility to the genome [62]. However,
these regulatory modifications are not limited to DNA and located in the nucleus, they can also target
RNA, proteins, and mitochondria, and be associated with disease [63,64].
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One well-known epigenome effector, which work as cellular sensors of metabolic status, are the
NAD+ dependent histone deacetylases sirtuins [65]. Sirtuins are a family of seven proteins involved
in different biological functions [66] such as DNA repair [67], apoptosis control [68,69], ROS and
oxidative stress regulation [70], together with their modulatory activity over enzymes from catabolism
to anabolism [71]. Some of them have mitochondrial location or activity [66,70].
The most studied sirtuins are Sirt1 and Sirt3. Genetic or pharmacological Sirt1 inhibition can
induce insulin resistance (IR) [72], and genetic Sirt1 variations have been associated with human
energy expenditure and obesity [73–75]. Moreover, the fasting state increases NAD+ levels and
activate metabolism through Sirt3 [76]. In the absence of Sirt3, cell and mitochondrial proteins become
hyperacetylated, contributing to the progression of metabolic diseases such as MetS [77,78].
4.3.2. miRNAs, mitomiRs, mitoRNAs, and xenomiRs
Non-coding ribonucleic acids (ncRNAs) are a wide heterogenous group of regulatory molecules
described in the last decades. Inside this group, there are micro-ribonucleic acids (miRNAS),
short molecules that prevent mRNA translation or induce transcripts degradation, thus preventing the
generation of the protein and associated function. These molecules are mostly located in the cytoplasm,
but there is a subset of about 150 different miRNAs, named mitomiRs, that have been also found in
the mitochondrial fraction [79]. Furthermore, the transcriptome of mitochondrial genome has also
revealed that it encodes multiple non-coding RNAs, which are named mitoRNAs [80]. Furthermore,
in the past few years, these molecules have been associated with several NCDs [81–83], including
MetS [84]. Interestingly, dietary changes in MetS patients associated with clinical improvements have
been linked to changes in miRNAs profile [85], as later depicted.
Nutrients can interplay at different levels with the human body. Their components can be the
anabolic precursors for the synthesis of complex molecules needed for cell survival. They can also
interplay at the chemical level with cell constituents; this is the case of the antioxidant effect. The last
findings support the idea that they can also regulate the expression of our genes. This is the case with
the xenomiRs, or food-derived miRNAs, exogenous miRs that emulate the function of our endogenous
miRs, exerting an additional mechanism of regulation for the expression of our genes. Despite there
being only few data available and plenty of polemics, some studies revealed an important concentration
of rice [86] or milk [87] xenomiRs in the plasma, after a dietary intervention. On the contrary, other
publications were unable to detect them [88,89]. Additionally, in case these xenomiRs were absorbed,
there is the crucial need to understand if they exert any function in our cells, as endogenous miRs do.
What is certain is that this field of study will be of growing interest in the next coming years.
4.4. Contribution of Mitochondrial (Dys)Function to MetS
The association between MetS and mitochondrial (dys)function has been suspected since long
ago and its contribution to the deterioration of the metabolic risk factors involved in the disease has
been studied.
Westernized diets, that usually include high caloric intake (high fat and/or sugars) might promote
an increase in the MRC activity that could lead to the overproduction of mitochondrial ROS [90].
In turn, the oxidative stress leads to reduced ATP production and decrease of the overall metabolism
in the cell, which is tightly associated with MetS [91–93]. Moreover, oxidative stress might contribute
to the appearance of insulin resistance (IR), defined as a decreased cellular response to physiological
insulin levels [94]. However, it remains unclear whether mitochondrial (dys)function is the main cause
of IR or vice-versa [95,96].
Furthermore, oxidative stress directly interferes in lipid oxidation, which results in an increased
cellular lipid accumulation (mainly diacylglycerols and ceramides), a situation that inhibits insulin
signaling [94,97,98]. This situation affects the translocation of the glucose transporter type 4 (Glut-44)
in insulin-sensitive tissues such muscle or fat [99], which leads to circulating glucose accumulation
and consequently, to hyperglycemia [100].
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Moreover, lipids and free fatty acids (FFA) also accumulate in the circulatory system, leading to
hypertriglyceridemia [101], which in turn promotes the increase of visceral adiposity and a modification
of fat distribution, and consequently the increase of waist circumference. This situation is caused
by the inability of adipose tissue to store the energy excess, so the FFA overload is accumulated
in the muscle, heart, liver, or as subcutaneous fat [102]. Under these conditions, fat redistribution
is accompanied by macrophages infiltration, which secrete proinflammatory molecules such as
interleukin-6 (IL-6), tumor necrosis factor (TNF), or C reactive protein (CRP), generating a low-grade
chronic inflammation state in MetS patients [103,104]. Furthermore, abdominal obesity correlates
with systemic levels of oxidative stress biomarkers [105,106] and defective mitochondrial biogenesis,
manifested by impaired mitochondrial dysfunction, which includes alterations in oxidative metabolism,
low mitochondrial gene expression, and reduced ATP generation [107,108]. Similarly, mitochondrial
alterations, increased oxidative stress, and low-grade chronic inflammation contribute to the etiology
of hypertension [109,110]. Finally, oxidative stress in also one of the main triggers of the formation and
progression of the atheroma plaque responsible of cardiovascular events included in the MetS.
5. Nutrients (Well-Being Through Feeding)
One of the best options to avoid, delay, or minimize risk factors contributing to MetS is changing
lifestyle routines, including a balanced diet.
5.1. Monounsaturated Fatty Acids (MUFAs)
MUFAs are fats with one unsaturation in their carbon chain. Dietary MUFAs can have different
origin, thus in Western diets, the supply is through foods of animal origin, whilst the main MUFAs
source in south European countries is extra virgin olive oil containing oleic acid [111]. Other sources of
MUFAs are the rest of vegetables oils and nuts such as macadamia nuts, hazelnuts, or pecans [112].
5.1.1. Some Extra Virgin Olive Oil Everywhere. Oleic Acid
Some cellular model studies have reported that oleic acid can have a positive role in mitochondrial
function. In fact, one study from in vitro modeling of β-pancreatic cells showed that oleic acid
enhances antioxidative defense [113]. Moreover, alternative studies demonstrated that oleic acid
supplementation reduces ROS generation and protects mitochondria from oxidative stress or
apoptosis [114,115]. Furthermore, oleic acid has been also reported as an anti-inflammatory modulator
through AMP-activated protein kinase (AMPK) activation and its activity among different targets
like nuclear factor kB (NF-kB) inhibition, and consequently, decreasing cytokines secretion such as
TNF [116–118].
In turn, oleic acid also enhances fatty acidβ-oxidation through AMPK response and interaction with
Sirt1 and the peroxisome proliferator-activated receptor gamma coactivator 1-alpha PGC-1α [119,120],
the master gene regulator of mitochondrial remodeling and biogenesis. Finally, oleic acid has been
demonstrated to increase the carnitine palmitoyl transferase 1 (CPT-1) level promoting the fatty
acid transport into mitochondria for β-oxidation [121,122]. Of note, most of these mechanisms have
been described using in vitro models responding to higher concentrations of oleic acid compared to
those obtained by food intake. Interestingly, several clinical benefits have been described with lower
doses (see Section 5.1.2). Further and deeper investigation is needed to validate the mechanisms and
dose-response effects of oleic acid, often observed in proof-of-concept studies.
5.1.2. Extra Virgin Olive Oil Against MetS
Systematic review and meta-analysis of cohort studies have demonstrated the positive effects of
oleic acid decreasing mortality risk (11%) and cardiovascular risk (12%) [123,124]. Focusing attention
on MetS, dietary MUFAs showed similar results [112]. In fact, clinical trials have demonstrated
a reduction of MetS risk factors such as blood pressure or total low-density lipoprotein (LDL)
cholesterol [125]. Moreover, also an improvement on insulin sensitivity and inflammatory response
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have been demonstrated using oleic acid in cell models [126] and randomized clinical trials [127]. Finally,
recent systematic review on human intervention studies with enriched oleic acid diets demonstrated
that this intervention can reduce central obesity and abdominal fat [128].
5.2. Polyunsaturated Fatty Acids (PUFAs)
PUFAs are fats with more than two unsaturations in their carbon chain that can be divided into two
main groups. Omega-3 fatty acids (α-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid)
mainly found in blue fish, eggs, and walnuts. In turn, the omega-6 group (linoleic acid, arachidonic
acid, and docosapentaenoic acid) are mostly founds in vegetable oils, such as sunflower, soybean, corn,
and canola oils.
5.2.1. More Blue Fish and Less Vegetal Oils. Omega-3 vs. Omega 6
Omega-3 PUFAs have been reported to act as mitochondrial protectors, as they reduce ROS
production and inflammation through the activation of AMPK. In turn, AMPK activates PGC-1α
which, together with the decrease in fission genes such as dynamin related protein 1 (DRP1), stimulates
mitochondrial function and fusion processes [129]. PGC-1α triggers different signaling pathways
that promote mitochondrial biogenesis, β-oxidation, glucose utilization, antioxidants detoxification,
and the activation of uncoupling proteins, which leads to a decrease in lipid accumulation and a
reduction of ROS [130–133]. It has also been described to attenuate ER-stress and the subsequent
disruption of Ca2+ homoeostasis. All these actions decrease the expression of pro-inflammatory
cytokines and attenuate the inflammasome, which improves insulin sensitivity [134]. Some animal
studies and clinical trials demonstrate that these actions would be triggered by changes in miRNAs
profiles, among others [135,136]. In addition, the reduction of the omega-6/omega-3 balance and the
omega-3 incorporation into mitochondrial membranes increase its viscosity. This situation improves
mitochondrial function and avoids cell dysfunction and cell death [137]. However, the disbalanced
omega-3/omega-6 ratio in detriment of omega-6 may also lead to adverse consequences, since excessive
omega-3 PUFAs may eventually trigger pro-oxidant and pro-inflammatory environments [138]. Thus,
the conservation of the omega-3/omega-6 ratio balance is key to avoid detrimental effects (Figure 3).
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Figure 3. Principal nutrients with beneficial effects on mitochondrial function. Oleic acid, omega-3,
selenium and zinc, resveratrol, lycopene, and the organosulfur compounds (OSCs) activate numerous
pathways, among them, direct or indirectly, PGC-1α signaling, one of the main coactivators and master
gene regulator of energy metabolism and mitochondrial biogenesis. The activation of the PGC-1α
promotes mitog nesis, β-oxidation, glucose utilization, uncoupling, and antioxi ant detoxification.
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Moreover, vitamin A and vitamins from the B group are essential for a correct functioning of the
glycolytic energy system, and vitamin C and oleic acid for the functioning of β-oxidation, among others.
One of the main effects of oleic acid, lycopene, organosulfur compounds (OSCs), vitamins B, C, D,
selenium, and zinc, catechins and olive oil polyphenols (OOPs) in our cells is the decrease of oxidative
stress by both promoting an antioxidant response and inhibiting pro-oxidant enzymes. Vitamin E
also acts as an antioxidant and maintains a correct mitochondrial structure, while omega-3 inhibits
mitochondrial fission. Omega-3 and vitamin D are involved in calcium homeostasis, among others.
Vitamin C, lycopene, and oleic acid have been reported to inhibit apoptosis, while oleic acid, omega-3,
and OSCs reduce inflammation.
5.2.2. Omega-3 PUFAs Against MetS
It is still controversial whether omega-6 PUFAs exert pro-inflammatory or anti-inflammatory
effects by themselves [139]. However, it is known that an unbalanced omega-6/omega-3 ratio in favor
of omega-6 PUFAs is highly prothrombotic and proinflammatory. The high amounts of omega-6
PUFAs present in Western diets, together with the very low amounts of omega-3 PUFAs, leads to an
unhealthy omega-6/omega-3 ratio that can reach a 20:1 proportion (instead the expected 1:1) [140],
contributing to atherosclerosis, obesity, and T2D [141] (Figure 4).
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constellation of pathologic conditions which incl hyperglycem a, insulin resistance, yslipidemia
(hypertriglyceridemia and low high density li rotein (HDL)-cholesterol levels), central obesity,
and hypertension. Several studies have demonstrated that nutrients such as oleic acid monounsaturated
fatty acid (MUFA), omega-3 polyunsaturated fatty acids (PUFAs), vitamins A, B, C, D, and E, selenium and
zinc elements, lycopene, olive oil polyphenols, resveratrol, organosulfured compounds, and catechins
have a positive impact on MEtS components, improving the onset and development of the disease.
Moreover, anim l studies have shown that a-3 improves insuli sensitivity and reduces
visceral fat storage [142, 3]. Differ nt rando i d clinical trials have proven that omega-3
supplementation produces favorable hypolipidemic effects, a reduction in pro-inflammatory cytokine
levels and improvement in glycaemia [144]. Animal and patient-based studies have shown that high
omega-3 intake and low omega-6/omega-3 ratio are associated with lower MetS risk [145,146].
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5.3. Vitamins
Vitamins are essential micronutrients for the proper functioning of metabolism. However, vitamins
cannot be synthesized by the organism, or not in enough amount, so they must be obtained through
diet. Vitamins can be classified into hydrosoluble (vitamins B and C) and liposoluble (vitamins A, D, E,
and K). Their biological properties will be discussed below.
5.3.1. A Varied Diet. Vitamins B
Vitamins B comprise a set of molecules found in a wide variety of food groups such as dairy
products (B2, B3, B5), eggs (B1, B3, B7, B12), fish and meat (B1, B3, B5,B6, B12), or plant-based foods
(B1, B5, B6, B9). Vitamins B are essential in the KC, so deficiencies in some of these vitamins will lead to
impaired mitochondrial metabolism, increased levels of mitochondrial ROS production, and decreased
overall energy production [147].
Vitamin B1 (thiamin) is a cofactor of several enzymes such as the cytosolic pyruvate dehydrogenase
or the mitochondrial ketoglutarate dehydrogenase; in vitro models demonstrate that its deficiency is
linked to increased ROS formation [148]. Vitamin B2 (riboflavin) is essential as a prosthetic group
for several enzymes catalyzing redox reactions; different studies demonstrated that its deficiency
is associated with a loss of mitochondrial complex IV and induced oxidative stress [149]. Vitamin
B3 (niacin) is an important cofactor involved in mitochondrial respiration reactions, glycolysis,
or lipid oxidation; B3 have also demonstrated to have an important antioxidant activity in different
investigations [150]. Vitamin B5 (pantothenic acid) is an important prosthetic group (CoA) involved
in KC and lipid metabolism; cellular models also demonstrated an important role in the enzymatic
antioxidant defense system promoting CAT, GR, or GPx [151]. Vitamin B6 (pyridoxal) have several
functions in different metabolic pathways such one-carbon reactions, gluconeogenesis, or lipid
metabolism, among others; even have an important antioxidant role through its activity in glutathione
pathways, demonstrated in cellular models [152]. Vitamin B7 (biotin) is an important cofactor for some
carboxylase enzymes involved in lipid metabolism; decreased B7 levels have been linked to increased
ROS formation and impaired mitochondrial respiration [153]. Vitamin B9 (folic acid) exerts different
biological functions like nucleotide synthesis or mitochondrial tRNA modification, among others;
folate contributes to cellular redox states preventing oxidative stress indirectly [154]. Finally, vitamin
B12 (cobalamin) is essential for nucleotide synthesis or succinyl-CoA generation; B12 deficiency has
been related to indirect increased ROS levels due to glutathione dysregulation in patients [155].
5.3.2. Orange Juice. Vitamin C
Vitamin C, or ascorbic acid, is principally found in pepper (and other vegetables) and fruits
(mainly in kiwi, guava, and citrus). This molecule is a potent antioxidant that activates Sirt1, triggering
a signaling cascade that decrease ROS and apoptosis and also acts as a ROS quencher. Moreover, it is
also involved in carnitine biosynthesis, the key factor in β-oxidation. Thus, vitamin C deficiency will
lead to impaired ATP production, β-oxidation deficiency, and ROS formation [156,157], and therefore,
mitochondrial dysfunction.
5.3.3. Carrot Cream. Vitamin A
Vitamin A or retinol is mainly found in carrots, sweet potatoes, or spinaches, as well as pork and
beef liver, which concentrate the highest amounts. This vitamin affects mitochondrial function as it
enhances the levels of the mitochondrial transcription factor A (mtTFA), a key transcription factor for
mitochondrial function, and plays a key role in glycolytic energy generation, as an essential cofactor
for protein kinase C delta (PKCδ), which signals the pyruvate dehydrogenase complex for an enhanced
flux of pyruvate into the KC [158]. Thus, deficiency of vitamin A has been associated with decreased
respiration and ATP synthesis [158–160].
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5.3.4. Slight Daily Sunbathe. Vitamin D
Vitamin D is naturally present in blue fish and egg yolks, among other foods. Furthermore,
vitamin D can be synthesized by the human body when ultraviolet rays from sunlight strike the skin.
However, after its obtention, either from sun exposure or food, it needs two hydroxylations to be
biologically active.
Many biological functions of vitamin D are mediated by the control of the vitamin D receptor
(VDR) on nuclear transcription. The VDR main function is to regulate Ca2+ homeostasis through the
upregulation of calcium transporters. Moreover, VDR protects from an excessive respiratory activity
and limits ROS production by controlling mitochondrial and nuclear transcription of the proteins
involved in MRC and ATP synthesis [161,162].
5.3.5. Avocado Is the Answer. Vitamin E
Vitamin E is mainly found in avocado, leafy vegetables such as spinach and broccoli, sunflower
seeds, nuts, and olive oil. Vitamin E is the most important antioxidant in cell membranes. It protects
mitochondrial structure and function by maintaining mitochondrial membrane integrity, allowing
the recovery of respiratory function and reducing lipid and protein oxidation [163]. This protective
function would be, in part, explained by the inhibition of lipid peroxidation and the increase in CAT,
SOD, GR, and GPx activity demonstrated in T2D rats [164].
5.3.6. Vitamins Against MetS
The role of vitamins in mitochondrial metabolism and their antioxidant properties suggest that they
might play a role in the prevention of MetS. Indeed, a case control-study showed that plasma levels of
vitamins A, C, E, and D were significantly lower in MetS patients compared to healthy subjects [165,166].
Different animal studies have suggested that vitamin A supplementation ameliorates
obesity through UPC1-mediated thermogenesis and delays the appearance of T2D by increasing
mtTFA [158,167]. Vitamin B7, biotin deficiency has been linked to impaired glucose tolerance,
hyperglycemia, and decreased glucose oxidation in animal studies [168] and a cross-sectional study
showed that high levels of vitamin B12 are protective to MetS [169]. Regarding vitamin C, different
patient-based studies have suggested that intake or supplementation decreases the risk of MetS and
improves the quality of life of MetS patients [169,170], especially when combined with physical
exercise [171,172]. Moreover, a cross-sectional study with more than 2000 patients demonstrated
that deficiency of vitamin C was associated with an increased likelihood of MetS [169]. Several
epidemiologic studies have established a strong association between vitamin D deficiency and
hypertension, obesity, and dyslipidemia [173,174]. In a randomized clinical trial with MetS patients,
vitamin E was seen to exert beneficial effects on cytokines and the lipid profile [175]. Moreover,
different studies have found that vitamin E could ameliorate the pathologic conditions associated with
MetS such as hyperglycemia or obesity, although more studies in patients are needed to prove the
consistency of these findings [175,176].
Nevertheless, when it comes to vitamins, overconsumption may be just as bad as scarcity.
For instance, an excess of vitamin A intake (with a tolerable upper intake level for adults of
3000 µg/day) [177] promotes oxidative stress and mitochondrial death [178] and it is associated
with an increased likelihood of MetS [160]. A high intake of vitamin B3 (niacin), can result in
niacin-induced IR [179], and when Vitamin C and E are consumed in excess, they promote prooxidants
activity instead of antioxidant function [147].
5.4. Trace Elements
Trace elements are minerals present in small amounts in living tissues. Some of them are
nutritionally essential and so need to be incorporated through diet, such as selenium or zinc, and others
are considered nonessential (or there is not consistent evidence to regard them as essentials) [180].
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5.4.1. A Handful of Nuts. Selenium and Zinc
Selenium and zinc are mainly present in nuts, mushrooms, fish, selfish, and meat, with antioxidant
and mitochondriogenic properties. Selenium promotes mitochondrial biogenesis through the
stimulation of PGC-1a, while the nuclear redox factor1 (NRF-1) generation exerts its antioxidant
role activating both GPx and GR enzymes. Some of these positive effects would be modulated by
selenium impact on miRNAs profile preventing oxidative stress and inflammation [181]. On the other
hand, zinc exerts its antioxidant power by promoting SOD and CAT activation, inhibiting important
pro-oxidant enzymes such as NADPH oxidase and competing with redox-active transition metals such
as iron and copper for certain binding sites (cell membranes, proteins), thereby prohibiting them from
catalyzing the formation of ROS and the initiation of lipid peroxidation [182].
5.4.2. Trace Elements Against MetS
Some studies have shown that adequate intake of these trace elements is associated with an
attenuation of MetS risk factors. In vivo and patient-based studies have found that recommended
doses of selenium (1–2 µg/kg/day) act as an insulin-mimetic, attenuating diabetes [183–185] and have
cardioprotective effects (increase plasma antioxidant capacity and decrease lipid peroxidation and
LDL-cholesterol) [186–188]. Additionally, a cross-sectional study including more than 2000 patients
showed that dietary selenium intake was negatively associated with MetS [170]. Regarding zinc, it is
involved in different protective mechanisms against obesity, IR, hypertension, and dyslipidemia, which
suggests potential roles of zinc in both the prevention and treatment of MetS. However, the current
scientific evidence in humans regarding the associations between zinc status and occurrence of MetS is
still inconsistent [189].
Despite these healthful and wellness properties of minerals, as it happens with vitamins, excess of
these elements is just as bad as a deficiency. Fortunately, severe impact on human health of vitamins
and minerals is only reached at very high concentrations. For instance, doses of selenium 100 times
higher than expected had adverse effects than at recommended doses by increasing the risk of T2D
and promoting CVD [190–192].
5.5. Polyphenols
Polyphenols are bioactive compounds with antioxidant properties mostly found in plant-based
foods [193]. According to their molecular structure, polyphenols can be categorized into two main
groups: flavonoids (such as catechins) and non-flavonoids, including phenolic acids (such as ellagic
acid), stilbenes (such as resveratrol), lignans (such as pinoresinol), and others (in which we find
oleuropein and hydroxytyrosol). Many of them show mitochondrial effects and have been reported to
modulate MetS [194].
5.5.1. A Cup of Green Tea. Catechins
Inside the flavonoids family, we find the catechins molecules, present mainly in green tea (with a
total minimum content of catechins of 8%), but also in a wide variety of fruits (Table 2). It has been
demonstrated that catechins can directly work as ROS scavengers and metal ions chelators and activate
some antioxidant enzymes such as CAT and SOD. Moreover, they can also inhibit some pro-oxidant
enzymes like NADPH-oxidase and suppress stress-related signaling pathways (as those mediated by
TNF or the activator protein 1). Some in vitro studies also demonstrated an anti-inflammatory effect of
catechins through changing miRNAs profile [195]. All together, these effects contribute to decrease
oxidative stress and improve mitochondrial function [196].
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Table 2. Summary of the principal nutrients with beneficial mitochondrial effects influencing metabolic syndrome.
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5.5.2. Some Black Grapes. Resveratrol
Resveratrol is another antioxidant, mainly found in black grapes. Resveratrol is a mitochondrial
protective agent. It activates Sirt1 which triggers different signaling pathways that promote antioxidant
and anti-inflammatory effects, and parallelly activate PGC-1α, the master regulator of mitochondrial
biogenesis. Sirt1 activation enhances β-oxidation and glucose utilization, promotes mitochondrial
biogenesis, antioxidant detoxification, and the expression of uncoupling proteins [233,234]. Moreover,
some of the anti-inflammatory effects of resveratrol are triggered by change in miRNAs profiles,
as demonstrated in cell models [235] and clinical human trials [236]. Of note, resveratrol is one of
those nutrients were herein reported beneficial in vitro effects have been observed with concentrations
usually beyond those reached by food intake. Notwithstanding, and regardless the mechanism,
clinically beneficial effects have also been reported [236]. Further studies are required to deepen in
dose-response effects of resveratrol, their interaction with other nutrients, and host metabolism.
5.5.3. A Spoon of Olive Oil. Oleuropein, Hydroxytyrosol, and Pinoresinol
Olive oil have a great content of polyphenols such as oleuropein (OL), hydroxytyrosol (HT), and
pinoresinol. Olive oil polyphenols (OOPs) are mitochondrial-protective agents for its antioxidant
properties. It has lately emerged that OOPs, particularly HT, are able to induce Sirt1 expression.
Moreover, Sirt1 interaction with nuclear redox factor 2 (NRF2) signaling, responsible for the
transcriptional activation of antistress target genes, exerts a protective effect against oxidative
stress. Furthermore, OL and HT can also scavenge ROS and OOPS have been demonstrated to
activate antioxidant enzymes such as GPx and CAT. Finally, HT has also been reported to stabilize
some mitochondrial complex-subunits and enhance the expression of PGC-1α and CPT-1 [204],
with previously reported mitochondrial activity.
5.5.4. Polyphenols Against MetS
Different studies have proven the beneficial effects of polyphenols in the prevention of MetS.
Animal studies have shown that green tea catechins lowers blood pressure by reducing ROS [199] and
have lipid-lowering activities [202]. Moreover, catechins and OOPs have been demonstrated to enhance
glucose tolerance and decrease events related to IR in both animal and human-based studies [203,204].
In addition, cardioprotective roles have been attributed to resveratrol and OOPs thanks to their ability
to counteract inflammation and reduce LDL-oxidation [204,207,208].
In humans, a meta-analysis of 20 randomized clinical trials, with a total of 1536 participants
who received green tea regularly, showed a slight decrease in systolic blood pressure and a
moderate reduction of LDL cholesterol [200]. Another study with 48 MetS patients demonstrated
that dietary achievable doses of blueberries significantly decreased blood pressure [201]. This blood
pressure-reducing effect has also been attributed to OOPs by different intervention studies [209].
Regarding resveratrol, a meta-analysis including 16 studies, 10 human-based and 6 in vivo studies,
showed that resveratrol intake meaningfully reduces the body weight, waist circumference, triglycerides,
and glucose level [205]. Moreover, a meta-analysis including 28 randomized clinical trials also
documented an improvement in obesity measures with resveratrol supplementation [206].
5.6. A Tomato Salad. Lycopene with Oleic Acid
Lycopene is a carotenoid found mainly in tomato, but also in other fruits such as watermelon,
papaya, or red grapefruits. The lycopene content increases during different stages of fruit ripening,
so the higher content of lycopene is found in ripe tomatoes [237].
However, lycopene undergoes photo-oxidation and degradation with light, which produces a
decrease in bioavailability. The incorporation of lycopene in an oil phase overcomes photo-oxidation.
An interesting option is the association of lycopene with olive oil, which prevents lycopene degradation
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and enriches its healthy properties with oleic acid, a monounsaturated fatty acid with antioxidant
properties [238,239].
Lycopene is also a powerful antioxidant and anti-inflammatory molecule. It acts as both ROS and
nitrogen species scavenger [240], decreases DNA damage [241–243], and modulates the production of
SOD and GPx [244,245]. Moreover, it promotes the expression of constructs containing antioxidant
response elements (ARE). Regarding its anti-inflammatory effects, lycopene reduces apoptosis as well
as the expression of inflammatory cytokines [246]. Lycopene also exerts lipid-lowering properties
through the induction of Sirt1 activity [247].
Lycopene Against MetS
Based on the potent antioxidant and lipid-lowering properties of lycopene, different studies have
assessed it as a beneficial nutrient for the prevention and treatment of MetS. Animal and human-based
studies have shown that lycopene reduces blood pressure [210,211], atherosclerotic burden [248] and
improves blood antioxidant capacity [246,249], has an anti-obesity role [212,213], improves insulin
sensitivity, reduces hyperglycemia [216,217], and improves the lipid profile [214,215]. Moreover,
a retrospective study with 2500 patients with MetS showed that higher serum levels of lycopene are
associated with a reduced risk of death [250].
5.7. Garlic Seasoning Is Always a Good Idea. Organosulfur Compounds (OSCs)
The OSCs comprise a group of molecules found in garlic that are accumulated as γ-glutamyl
peptides. Depending on the processing status of the garlic, different OSCs can be present: alliin and
sulfur amino acids from whole cloves, allicin from crushed cloves, ajoene and vinyldithiines from
stir-fried garlic, and (poly)sulfides from steam-distilled garlic oil. However, the main active metabolite
responsible for most of the biological activities of garlic is allicin [251].
The OSCs are potent antioxidant molecules, they decrease the activity of pro-oxidant molecules,
such as NADPH oxidase, and increase the activity of antioxidant proteins, such as NRF2 [252,253].
Moreover, they also activate Sirt3, which prevents cardiac oxidative stress and mitochondrial
dysfunction [224]. OSCs have also anti-inflammatory effects, as they suppress the activation of
proinflammatory molecules such as NF-kB or TNF [254,255].
OSCs against MetS
In vitro and in vivo studies have highlighted the anti-adipogenic effect of OSCs through the
promotion of mitochondrial uncoupling (increasing the expression of UPC-1) and the inhibition of
adipocyte differentiation (through AMPK activation) [218–221], as well as their cardioprotective effects
(decrease plasmatic insulin, total cholesterol, and oxidative stress levels) [224,225]. The cardioprotective
effects of garlic have also been demonstrated in patient-based studies [226].
Moreover, different intervention studies have shown that garlic supplementation attenuates MetS
abnormalities: reduces hypertension [222,227,256], improves lipid profile [222,223], decreases waist
circumference and fasting blood glucose [222].
6. The Impact of Gut Microbiome on MetS. between Nutrients and Mitochondria
The human intestines are home to a vast number of bacteria, archaea, microbial eukaryotes,
and viruses, collectively known as the gut microbiome [257]. Nutrients can modify microbiome
composition (this is the case of yogurts and pickles) and, at the same time, microbiome can condition
the absorption of some nutrients and, thus, our health. That is why gut microbiome can be considered
another intrinsic factor contributing to MetS, and many other conditions.
Diet is accepted as the first driver of gut microbiome composition and not only the cause
of preventable diseases. In 2007, it was demonstrated that a high-fat-diet affects the intestinal
barrier leading the pass of microbiota products to systemic circulation. These molecules, such
as lipopolysaccharide (LPS), showed deleterious effects on glycaemic function and activated the
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inflammatory response [258]. Recently, LPS has been also related to plasmatic decrease in high-density
lipoprotein (HDL) cholesterol and increase in triglycerides [259,260].
In fact, the gut microbiome responds to diet composition [261], including changes depending on
fat composition [262,263], fiber types [264,265], and food additives [266]. Moreov73er, some dietary
interventions demonstrated changes in the microbiome population that negatively correlated with
obesity and hypertension [267–269]. Some others do not. This is the case of dietary interventions with
polyphenols in MetS patients, that despite decreasing the expression of MetS biomarkers, yielded to
null differences in gut microbiota when compared to healthy subjects [270].
Furthermore, also gut microbiome metabolic end products like the short-chain fatty acids
(SCFAs) that may play a role in MetS. Some SCFAs like butyrate appear diminished in inflammatory
diseases [271,272], whilst another SCFAs study with propionate supplementation improved visceral
adipose tissue levels and maintained insulin sensitivity [273]. Additionally, when produced in high
amounts, these molecules have been also involved in obesity, among others [274].
Finally, gut microbiome can synthesize vitamin K, necessary for normal clotting activity, and some
B vitamins, contributing to more than a quarter of the daily reference intake in the case of B3, B6,
B9, and B12 [275]. All these vitamins are cofactors of some metabolic routes involved in proper
mitochondrial function.
Beyond food and food compounds, some other interventions have an impact on gut microbiome
and, consequently, on host metabolism, such as prebiotics, probiotics, and also fecal microbiome
transplantation (FMT). Prebiotics are defined as non-digestible polysaccharides that promote
“the selective stimulation of growth and/or activity(ies) of one or a limited number of microbial
genus(era)/species in the gut microbiota that confer(s) health benefit to the host” [276]. In turn,
probiotics are defined as “live microorganisms which when administered in adequate amounts,
confer a beneficial health effect on the host” [277]. Several studies have been conducted in animal
models [278–280] and humans [281–284], demonstrating benefits such as decrease in serum glucose,
visceral fat area, waist circumference, or cholesterol levels. However, these results have not been
always reproduced [285,286]. Finally, FMT has demonstrated that it can help reverse obesity in rodents,
although there is no evidence in humans [287]. However, FMT has demonstrated to increase insulin
sensitivity in MetS patients [288,289].
All these data suggest a role of gut microbiome in MetS, conditioning the interplay and effects
of nutrient intake within the organism. However, this research area is quite novel and needs further
assessment to understand the complex interactions between gut microbiome and its host.
7. Diet as a Therapy
7.1. Healthy Diet Base: Which Food and in Which Context
The nutrients and bioactive compounds reviewed above are just an example of the beneficial
impact of some dietary patterns to avoid the onset and development of MetS and its associated
complications. They exert a multitude of healthy actions, some of them through the modulation of
mitochondrial functions.
For that purpose, dietary habits should focus on what and how we eat rather than on nutrients.
This means predominating plant-based foods and fish, typical from the traditional MedDiet [290]
rather than supplementation containing the nutrients or bioactive compounds (except for specific
situations). Accordingly, a recent meta-analysis has shown that a prudent/healthy dietary pattern is a
protective factor for MetS [291].
Nevertheless, multiple additional factors must be considered to achieve a health-promoting
lifestyle. For instance, proper hydration it is very important. According to the European Food
Safety Authority (EFSA) the adequate intake of daily total water for women and men is 2 and 2.5 L,
respectively [292]. In fact, suboptimal hydration has an impact on health [293], metabolism [294] and
T2D [295].
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Additionally, a healthy lifestyle must minimize elements that have negative effect on health,
and particularly on MetS such as tobacco [296], alcohol [297], or physical inactivity [298].
Moreover, related to the physical inactivity, some regular exercise has a positive impact on disease
and on personal well-being [299]. Physical activity enhances energy consumption and reduces the
risk of prevalent diseases such as T2D, CVD, and MetS [300]. Because of the increase of energy
consumption, the metabolic disturbances associated with MetS such as increased blood glucose,
triglycerides, or inflammation improve [300,301].
However, we must be careful with the intensity of physical exercise and avoid acute trainings,
which has been related to an increase of ROS production [302]. For that purpose, the most beneficial
practice will be moderate intensity training, promoting the proper balance between the ROS generation
and the increase in the antioxidant defense [303].
7.2. Ketogenic Diet and Mitohormesis
Under some extreme situations, as primary mitochondrial diseases, changes in diet recommended
by trained professionals may help to reconfigure mitochondrial activity and consequently, adverse
clinical features [11,304].
This is the case of the ketogenic diet (KD), based on the intake of high-fat vs. low-carbohydrates
content. This situation mimics starvation, forcing the body to use fat as energy source. Fatty acid
oxidation results in ketogenesis [305] in the liver, with the consequent exportation of ketonic bodies
throughout the rest of the body.
This diet must be prescribed and monitored by professionals to assess benefits and manage side
effects [306]. Surprisingly, KD has shown anticonvulsant properties, at the clinical level, and the
modulation of mitochondrial biogenesis [307] and the regulation of the levels of hormones or
neurotransmitters [308], at the molecular level. These effects can be explained, at least in part,
for an adaptive response called mitohormesis. Mitohormesis can be defined as the biological response
where the induction of a reduced amount of mitochondrial stress leads to an increment in health and
viability within a cell, tissue, or organism [309]. In this case, fat consumption would promote modest
ROS increase, stimulating cell proliferation, differentiation, immunity, and adaptations that would
eventually (and surprisingly) lead to enhancing resistance to oxidative stress in mitochondria [310,311].
About 25–30% of epilepsy patients worldwide show resistance to any pharmacological
management (refractory epilepsy). Experiences on KD have shown a reduction in seizures greater
than 50% [312,313], although the explanation for this effect remains unclear [314,315].
In inherited metabolic diseases such as Leigh syndrome, glucose transporter type 1 (Glut-1)
and pyruvate dehydrogenase complex (PDH) deficiency and in a subset of patients with complex I
deficiency [305,308], KD has also demonstrated to be useful. Under KD, most patients with epilepsy
become seizure free and improve speech, motor, and mental development, and ability [316] despite its
use is only partially able to reverse the clinical course of the neurodegenerative condition [317].
7.3. Enhancing MRC and Energy Buffering. Mitochondrial Burst
Some other mitochondrial diseases, contrarily, require the supplementation with CoQ10, riboflavin
(vitamin B2), or thiamine (vitamin B1) to enhance ETC, or with creatine monohydrate, to increase
energy buffering.
In some genetic diseases affecting enzymes involved in CoQ10 synthesis [318], supplementation
can improve the clinical symptoms related to this deficiency [319]. Supplementation with riboflavin,
a key building block in complex I and II, has particular usefulness in acyl-CoA dehydrogenase-9
(ACAD9) deficiency, resulting in increased complex I activity [320,321] and in the multiple acyl-CoA
dehydrogenase deficiency caused by mutations in electron-transport flavoprotein dehydrogenase
(ETFDH) [322,323]. Thiamine has been used, alone or in combination with other molecules, in the
treatment of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes),
improving the symptoms of myopathy and lactic acidosis [324] and Leigh syndrome [325].
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Finally, creatine binding to phosphate in the mitochondria is the main source of high energy
in anaerobic metabolism. High energy demanding tissues like muscle or brain present the highest
creatine levels [326]. In mitochondrial myopathy, the content of phosphocreatine is decreased [327],
which is why supplementation with creatine monohydrate effectively improves the motor ability of
patients with mitochondrial myopathy [328].
As explained, the complexity of dietary treatments for mitochondrial diseases requires the
intervention of multidisciplinary and specialized units from clinical settings where both clinicians
and dieticians design the proper treatment (including dietary interventions) for each affected patient.
Although some recommendations may be similar, the dietetic support for mitochondrial diseases is set
apart from the management of MetS.
8. Conclusions
The evidence herein discussed highlights the association of mitochondrial (dys)function with
MetS. However, whether mitochondrial defects can be understood as a cause or consequence of MetS
remains to be clarified. Similarly, whether all nutrients reach mitochondria and at which food dose
do exert their beneficial effects is still controversial. In this sense, in vitro studies usually work with
higher concentrations that significantly differ from those that are reached in human interventions
and must be considered as models to understand molecular mechanisms difficult to approach in vivo.
All approaches are needed to understand the interplay between nutrients, mitochondria, and MetS,
or disease in general, where the effects of nutrients will differ also depending on their dose, their acute or
chronic consumption, and their interaction with other food components or host characteristics. Despite
growing interests, the complexity of reality is still far beyond current knowledge and information
provided in the present review challenge new researchers to develop novel approaches. Whether
nutrients exert their protective effect against MetS exclusively through mitochondria or by deploying a
panoply of molecular effects beyond it, is also under consideration, at least for some of them.
However, some mitochondrial effects have been extensively documented in cell and animal models,
as well as in patients. In particular, the above reviewed nutrients and bioactive compounds have been
proved to improve mitochondrial function. In fact, oleic acid, omega-3, vitamins B and C, selenium/zinc,
polyphenols, lycopene, and OSCs have been documented to improve mitochondrial antioxidant defense
and reduce oxidative stress; oleic acid, lycopene, and OSCs have a potent anti-inflammatory role;
vitamins A, B, and C are essential for mitochondrial energy generation; vitamin D and omega-3
regulate calcium homeostasis; vitamin E protects the mitochondrial structure; and selenium/zinc and
some polyphenols stimulate mitochondrial biogenesis. At the same time, the consumption of all these
elements has been associated with the reduction of MetS risk factors.
All this evidence confirms that a balanced diet represents a valuable therapeutic strategy to
improve the global metabolic state, among others, through the enhancement of mitochondrial function.
However, is not the intake of any of these isolated compounds by their own, as dietary supplements,
but the synergic interplay of them all in foods and meals which makes the difference (for instance,
lycopene of tomato with olive oil). Similarly, the excess of most of them in a diet is as bad as their
absence. This is the case of the antioxidant paradox, since most of antioxidants, upon athreshold,
become prooxidants compounds. In most cases, the balance is the key to obtain healthy effects within
a diet. This is also the case of the intake of some foods such as fatty fish, with healthy effects for their
composition in omega 3, but also prone to accumulate traces of some heavy metals and other pollutants
with toxic effects at the nervous but also the cardiovascular system [329,330]. In these cases, moderate
consumption is the best choice to promote healthy benefits.
Additionally, diet must not be the unique lifestyle intervention to ameliorate mitochondrial
activity and MetS. In this regard, moderated physical activity has been also demonstrated to prevent
and/or improve the metabolic alterations related with mitochondrial dys(function), as well as MetS,
together with avoiding mitochondrial toxic drugs (as tobacco or alcohol).
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In conclusion, following a balanced diet, like the MedDiet or traditional Asian diets, protects
against the MetS (and many other diseases). The best medicine is in our hands; cheap, tasty, and close.
However, the exact formula does not exist, maybe because it is specific for each subject. Despite all the
advances in understanding the role of nutrition in mitochondrial function, the perfect dietary patterns
and nutrients combination to preserve/enhance mitochondrial activity remains unclear, as well as
how these dietary patterns get translated in enhanced metabolic health. For that purpose, further
studies must be undertaken to fully understand the impact of a balanced diet on global/mitochondrial
health. Moreover, a better comprehension of some novel intrinsic factors, such as gut microbiota
interactions with nutrients and host metabolism, and extrinsic factors, such as the induced epigenetic
response to dietary patterns, would contribute to the understanding of the complexity of the nutritional
impact on health. Such findings should be effective for the development of the appropriate dietary
interventions that may lead to avoid the onset and the development of one of the major health problems
in the modern society, MetS. Interestingly, personalized medicine and individual dietary patterns will
probably set the path for novel therapeutics and preventive medicine in coming years.
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